Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylam's RNA-interference technology. Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts.

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

The Pasteur Institute of Lille (French: Institut Pasteur de Lille, Pasteur-Lille, IPL) is a research centre and member of the Pasteur Institute network. It includes 14 research units and 1,150 employees including 626 researchers located in Lille, France. There are also 300 employees located outside the Pasteur site. Its revenues are above €70 million. Several neuroscience start-up companies have emerged from the Pasteur Institute of Lille.

Helmholtz-Zentrum für Infektionsforschung GmbH provides bio-medical research and development services. The firm engages in research projects focused on infection biology and its clinical application and practical implementation. It also specializes in the examination of pathogens that are either medically relevant or that can be used as models for the research of infections. Its research topics encompass bacterial and viral pathogens, immune response, and anti-infectives. The company was founded in 1965 and is headquartered in Braunschweig, Germany.

Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany.

Cleveland BioLabs is a clinical-stage biotech developing a robust pipeline of drugs for multiple medical and defense applications, with a focus on oncology and tissue protection. The company pursues the research, development, and commercialization of proprietary products that have the potential to treat cancer, prevent, and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients. Cleveland BioLabs was established in 2003 and is headquartered in Buffalo, New York.

Merck Sharp & Dohme Corp. engages in the research, development, and distribution of vaccines, prescription drugs, and animal health products. The company is headquartered in Whitehouse Station, NJ.

Bayer CropScience LP provides crop protection products. The company was founded on December 3, 1999 and is headquartered in Research Triangle Park, NC.

Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland.

Virometix AG is a private company headquartered in Schlieren, Switzerland, that operates as biotechnology company, which develops vaccines and immunotherapeutic drugs for prevention and treatment of infectious and chronic human diseases. It was founded by John Anthony Robinson. Anna Sumeray is currently the CEO of the firm.\nThe company says this about itself: Virometix AG is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infections and cancer. In an increasingly global world, there is a considerable medical need for vaccines to combat infectious as well as a number of chronic human diseases, including cancer. Rational molecular design, chemical synthesis and Virometix' proprietary “Synthetic Virus-Like Particle” platform technology allow for the rapid production and optimization of vaccine candidates with the potential to demonstrate superior properties in terms of safety, efficacy and stability.

Helix BioMedix is specialty dermatology and consumer products skin health company developing bioactive peptides for uses across a wide range of markets. Our mission is to enrich clinical practice and the patient/consumer experience by developing topically-applied products which offer the health, beauty and safety benefits of our advanced bioactive small molecule technology. Our vision is to be recognized as the world leader in the identification, qualification and commercialization of natural and synthetic peptides.

Kaneka Corp. engages in the manufacture and sale of chemicals, synthetic resins, and plastics. It operates through the following segments: Material Solutions, Quality of Life Solutions, Health Care Solutions, Nutrition Solutions and Others. The Material Solutions segment covers biodegradable polymers, materials that support the development of social infrastructure and mobility which includes the weight reduction and fuel efficiency improvement. The Quality of Life Solutions segment handles energy saving needs such as housing and living infrastructure, and development of Internet of things (IoT) and artificial intelligence (AI). The Health Care Solutions segment offers solutions through the fusion of devices and medicines, and develops healthcare business based on biopharmaceuticals and regenerative and cellular medicines. The Nutrition Solutions segment provides materials and supplement solutions to food production support in livestock and fishery industries. The Others segment provides agency services for property and life insurance. The company was founded on September 1, 1949 and is headquartered in Osaka, Japan.

Develops vaccines and immune enhancers diagnostic substances

TherimuneX™ is a bio-pharmaceutical research and development company. The mission of the Company is to fully exploit the commercial applications of a new medical discovery by Dr. James D. Thacker, PhD. The role of inflammation in health and disease has been debated since the middle of the 19th century. The focus of their research at TherimuneX™ stands upon the seminal work of the late Prof. Jurg Tschopp and the discovery of the inflammasome signaling platform. They have extended this work and related inflammasome signaling to endoplasmic reticulum (ER) stress, the unfolded protein response (UPR), and the genesis and progression of chronic diseases. They have also shown that Naclynamide effectively resolves the excess collagen production in cells from Scleroderma patients and reverts these cells from their diseased phenotype (myofibrolasts) to the normal phenotype (fibroblasts). They expect to file their IND within the next 12 months for the use of Naclynamide™ in the treatment of diffuse Scleroderma. They plan to follow with the use of Naclynamide™ in related diseases. Standing upon their discoveries, they have developed a new drug candidate, Naclynamide, that they have already shown to be safe and effective in two different cancers in dogs that were resistant to conventional chemotherapy. Canine cancer is widely regarded to be the same disease as human cancer. They believe that this is related to a shared microbiome that has developed from co-evolution of dogs and man. Moreover, they believe that chronic/persistent/latent infection accounts for several types of cancer as well as the prevalence/incidence of many cancers. They are planning to follow lead indication with an indication for the treatment of selected cancers. They have established the proof of principle for Naclynamide™ use as a pre-exposure and post-exposure drug candidate in animal models of a lethal Gram negative bacterial infection and a drug resistant MRSA infection. Their published research has clearly established the enhanced innate immune response and recruitment and activation of immune cells and a potent opsono-phagocytic and cytotoxic T-lymphocyte response as the mode of action for Naclynamide™ (Adamson, et al. Cancer Biology & Therapy 2014, 15(4), 1-11). Their molecular biology studies have shown the intracellular protein target of Naclynamide™ to be XBP1 and they have elucidated the down-stream signaling pathway through NLRP3 inflammasome activation and innate and adaptive immune gene up-regulation. Their collaborator, Brian Balin, as well as investigators from other institutions, have been promoting the idea that chronic/persistent/latent infection may lead to Alzheimer’s Disease. They have shown that Naclynamide™ effectively eliminates obligate intracellular pathogens and may be effective as a treatment. Because Naclynamide™ has potent anti-fibrotic activity, they are presently evaluating its efficacy in idiopathic pulmonary fibrosis. Preliminary results indicate a similar efficacy in this disease. Therefore, they intend to seek approval for use of Naclynamide™ in this disease as well. Their advisory board is led by Dr. Phil Gerbino. Dr. Gerbino is a Fellow of the College of Physicians of Philadelphia; the American Pharmacists Association (APhA), Academy of Pharmacy Practice and Management; and the American Society of Consultant Pharmacists (ASCP). He received the 2010 Frank Baldino Jr., CEO of the Year Award from Pennsylvania Bio was recognized in PharmaVoice, 2005, Top 100 as a “Change Agent”. He is the recipient of national leadership awards including those from Merck, Hoechst-Roussel, Parke-Davis, Upjohn, Procter & Gamble and others.

Lipofabrik produces and markets biological and biodegradable molecules produced through bioprocesses based on renewable resources. LIPOFABRIK presently produces 6 different types of lipopeptides: Fengycin, Plipastatin, Iturin, Lichenysin, Mycosubtilin, Surfactin.

Kemin Industries, Inc. develops and manufactures nutritional ingredients. It operates through two business units: Animal Nutrition & Health and Food & Human. The Animal Nutrition & Health business unit offers products that provide nutrition and health benefits for animals. The business unit?s products include ButiPEARL, ButiPEARL Z, CholiPEARL, CLOSTAT, ENDOX and FRESH CUT Plus. The Food & Human business unit offers products that benefits human health. The business unit?s products include AssuriTEA, FloraGLO, Neumentix, Slendesta and XSurge. The firm manufactures specialty ingredients for the global feed and food industries as well as the health, nutrition and beauty markets. The company operates offices and manufacturing facilities in Asia Pacific, China, EMEA, India, North America and South America regions. Kemin Industries was founded by Rolland W. Nelson and Mary Ann Nelson in 1961 and is headquartered in Des Moines, IA.

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing clinically effective anti-infective treatments against serious and often life-threatening infections. With over 100 years of pharmaceutical industry expertise, we are a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and finished dosage forms (FDF), and the world-leading supplier of Vancomycin and Colistimethate Sodium (CMS). Our range of anti-infective treatments combat, most types of bacterial and antibiotic-resistant infections and certain fungal diseases. We have growing sales in more than 70 countries to over 700 customers and are continually developing and expanding our product range to meet new treatment needs and to better service our customers’ requirements. This includes developing new dosage forms using Xellia’s APIs, and if required APIs sourced from our network of suppliers. To complement our dry powder fill and freeze-dried vials for injectable delivery we are also developing innovative proprietary delivery systems and formulations for topical, inhaled or injectable administration either in house or through partnerships. We also offer contract manufacturing services and custom synthesis for clinical trial material supply. Xellia is a private company, with more than 850 employees and four state-of-the-art manufacturing facilities in Norway, Denmark, Hungary and China. We operate according to current Good Manufacturing Practice (cGMP) and our facilities have received regulatory approval from all relevant authorities, including the US Food and Drug Administration (FDA). Our operational headquarters are in Copenhagen, Denmark.

The Institute Pasteur is a private, non-profit foundation. Its mission is to help prevent and treat diseases, mainly those of infectious origin, through research, teaching, and public health initiatives.The Institut Pasteur is a research center of international renown ideally located in the very heart of Paris. Each year the institute hosts a multitude of scientific and medical conferences and meetings as well as events on a variety of themes.